Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05505409
Other study ID # PFD-CTD-ILD QiluH
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 22, 2022
Est. completion date December 1, 2025

Study information

Verified date November 2022
Source Qilu Hospital of Shandong University
Contact Qiang Shu, Dr
Phone 0086-0531-82169654
Email shuqiang@sdu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single-center randomized controlled study will be used to observe the efficacy and safety of pirfenidone on CTD-ILD patients for 24 months. The main research endpoints is the lung function (FVC) at 6 months. The clinical dyspnea score, 6-minute walking distance, index of lung function and imaging indicators are evaluated, as well as primary disease activity and adverse reactions of therapy with glucocorticoid and immunosuppressants up to 24 months.


Description:

A total of 120 Chinese patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), including inflammatory myopathy (IIM), rheumatoid arthritis (RA), systemic sclerosis (SSc), and other connective tissue diseases, will be enrolled to use Pirfenidone or not in this study according to 2:1 random entry. Glucocorticoid and immunosuppressants worked as background treatment. The main research endpoint is the lung function (FVC) at 6 months. The clinical dyspnea score, 6-minute walking distance, lung function and imaging indicators, primary disease activity index are evaluated regularly until 24 months. The relationship of pirfenidone concentration, clinical effect and safety, immune function will be analyzed also.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 1, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility 1. Age =18 years; 2. Meet several CTD diagnostic criteria (RA, IIM, SSc) and UCTD/IPAF classification criteria; 3. HRCT diagnosis confirmed interstitial lung disease (ILD) with corresponding clinical manifestations; 4. Patients who were able to complete vital capacity (FVC) or carbon monoxide dispersion (DLco) tests (with Hb correction). 5. Patients with clinical deterioration more than 1 month after diagnosis of ILD history, or poor response or intolerance to Glucocorticoids or immunosuppressants treatment, or poor response or intolerance to other antifibrotic drugs (acetyl hemitrine, nidanib, etc.), or effective use of PFD, and exacerbation of clinical symptoms or ILD indicators more than 3 months after withdrawal of the drug. 6. Poor response was defined as no improvement in one of the following: (1) Symptoms of dyspnea such as cough, chest tightness, breathlessness, shortness of breath after activity, or decreased activity endurance; (2) the worst decrease in oxygen saturation as measured by pulse oxygen saturation (SpO2) observed during 6MWD; (3) There was no improvement in pulmonary ventilation (FVC%) or lung dispersion (DLco%); (4) HRCT findings: new onset, fibrosis tendency or density of ILD lesions were not decreased; Clinical deterioration was defined as meeting one of three criteria: 1. Clinical deterioration or dyspnea within 4 weeks; 2. New or worsening radiological abnormalities on chest X-ray or high-resolution CT; 3. Objective deterioration of pulmonary function tests or gas exchange, defined as meeting at least one of the following criteria: 1) Start long-term oxygen therapy or increase oxygen supplementation by at least 1 L/min to maintain resting oxygen saturation of at least 90%; 2) FVC decreased by more than 5% compared with the previously measured value; Or a decrease in DLCO of more than 10% from previous measurements; Or a 20% decrease in 6MWD from previous measurements. 7. If concomitant therapy with immunosuppressants was used, the dose was stable for at least 4 weeks before the baseline period. The types of immunomodulator hydroxychloroquine (HCQ) or immunosuppressive agents are MMF, TAC, JAKi, CTX, LEF, AzA, iguratimod etc. 8. Concomitant glucocorticoids: IIM patients with glucocorticoids dose (calculated as the equivalent dose of prednisone) =60mg/d and relatively stable disease; For other CTD patients, the glucocorticoids dose (calculated as prednisone equivalent dose) was =40mg/ day for at least 1 month. Exclusion Criteria: 1. Subjects have systemic vasculitis, other arthritis other than CTD or RA such AS psoriatic arthritis, SPA, AS, SLE and pSS; 2. ILD patients with other obvious causes, such as HIV, GVHD, etc. 3. Patients with obvious abnormal combined organ function; 1. Liver :AST, ALT, R-GT, bilirubin at 1.5 ULN, or previously diagnosed viral hepatitis; 2. Kidney: creatinine clearance rate 30ml /min; 3. Lung: airway obstruction (pre-bronchodilator FEV1/FVC & LT; 0.7), pleural effusion accounted for more than 20% of pleural effusion, severe pulmonary infection or other clinically significant pulmonary abnormalities; 4. Cardiovascular: myocardial infarction within 6 months; 5. gastrointestinal tract: active peptic ulcer or bleeding; 6. Blood system: severe anemia, leukopenia, thrombocytopenia; 7. Nervous system: patients with mental disorders; Cerebral thrombotic events (stroke and transient ischemic attack) within the last 1 year; 4. Tuberculosis, cancer, hereditary diseases and other diseases with poor prognosis; 5. Effective contraception cannot be guaranteed during pregnancy, lactation or childbearing age; 6. Evidence of alcohol or drug abuse, according to the researchers; 7. Allergic to glucocorticoids, immunosuppressants and PFD; 8. Unable to complete regular follow-up and post-treatment pulmonary function tests; 9. PFD users not included in the efficacy analysis but included in the safety analysis: those who had used PFD for less than 3 months 6 months before the primary endpoint; The duration of use was less than 3 months before the 24th month of the syudy and the total duration of use was less than 6 months.

Study Design


Intervention

Drug:
Pirfenidone
Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
glucocorticoid and immunosuppressant
Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease

Locations

Country Name City State
China Qilu Hospital Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in FVC% change in percentage of forced vital capacity (FVC) from 6 months to baseline 6 months
Secondary Change in FVC % change from baseline in percentage of forced vital capacity (FVC) 3months 12 months 24 months
Secondary change in FEV1%?DLco%?TLC% change from baseline in carbon monoxide diffusing capacity (DLco)?FEV1?TLC 3months 6months 12months 24months
Secondary Proportion of patients and time with a decrease in DLco% Percentage of patients and time with DLco% decreased>15% compared to baseline 3months 6months 12months 24months
Secondary Proportion of patients and time with a decrease in FVC% Percentage of patients and time with FVC% decreased>10% compared to baseline 3months 6months 12months 24months
Secondary Progression-free survival survival with a predicated absolute FVC% decrease of no more than 10% from baseline,and a predicated absolute DLco% decrease of no more than 15% from baseline up to 24months
Secondary change in absolute value of FVC and DLco absolute value change of FVC(ml) and DLco(ml) at each time point and annual decline rate compared with baseline 3months 6months 12months 24months
Secondary changes from baseline in 6 minutes walking distance changes from baseline in 6 minutes walking distance 3months 6months 12months 24months
Secondary change in pulse oxygen saturation the worst oxygen saturation as measured by pulse oxygen saturation(SpO2) was observed during 6 minutes walking distance up to 24months
Secondary Worsening respiratory symptoms Proportion of patients with worsening respiratory symptoms at each time point compared with baseline 3 months 6months 12months 24months
Secondary Advances in imaging The proportion of patients with disease progression on imaging at each time point compared with baseline 3 months 6months 12months 24months
Secondary Imaging changes changes from baseline in high-resolution computed tomography (HRCT) 6months 12months 24months
Secondary Borg dyspnea Index score cChange of Borg dyspnea index score at each time point compared with baseline 3 months 6months 12months 24months
Secondary clinical deteriorration The time and incidence of the first clinical deterioration ,Number of clinical exacerbations,Time between the all-cause deaths up to 24months
Secondary Changes from baseline in C-reactive protein (CRP),Erythrocyte Sedimentation Rate(ESR),Inflammatory factors and indicators. Changes from baseline in C-reactive protein (CRP),Erythrocyte Sedimentation Rate(ESR),Inflammatory factors and indicators. 3 months 6months 12months 24months
Secondary Changes from baseline in primary disease activity Changes from baseline in primary disease activity up to 24months
Secondary Adverse events , timing,type,extent,frequency,and outcome of SAE Adverse events , timing,type,extent,frequency,and outcome of SAE up to 24months
Secondary FVC% area under the curve forced vital capacity (FVC)% area under the curve 3months 6months 12months 24months
Secondary Predicators of pirfenidone response in each disease subgroup Predicators of pirfenidone response in each disease subgroup 3months 6months 12months 24months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Recruiting NCT05417776 - Collagen-targeted PET Imaging for Early Interstitial Lung Disease Phase 2
Not yet recruiting NCT04089826 - Long Term Oxygen Therapy in Patients With Interstitial Lung Disease
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT00883129 - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Phase 2
Completed NCT00362739 - Blood Collection From Individuals With Lung Disease for Genetic Studies N/A
Recruiting NCT06133998 - Effects of Incentive Spirometry With and Without Aerobic Exercises in Interstitial Lung Disease N/A
Active, not recruiting NCT03485378 - Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease N/A
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting NCT03400839 - Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases
Terminated NCT02633293 - An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Phase 2/Phase 3
Enrolling by invitation NCT05001009 - Goals of Care Conversations Study N/A
Active, not recruiting NCT05068869 - Digital Outpatient Services N/A
Active, not recruiting NCT03727568 - Study Comparing Two Different Methods of Cryobiopsy in the Interstitial Lung Diseases N/A
Recruiting NCT06046547 - Integrating Palliative Care Education in Pulmonary Rehabilitation N/A
Completed NCT04946708 - Virtual Exercise Program in Interstitial Lung Disease (ILD) Patients N/A
Recruiting NCT04139356 - The Effect of Spontaneous Respiration on Pulse-oximetry Measurements N/A
Recruiting NCT03726398 - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Phase 2/Phase 3
Active, not recruiting NCT03295279 - WTC Chest CT Imaging Archive